ArticleClinical ophthalmology (Auckland, N.Z.)2011
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.
Article in Clinical ophthalmology (Auckland, N.Z.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Bacterial profile of ocular infections: a systematic review.BMC ophthalmology · 2017Pooled it
- Recent advances in piperazine derivatives as antibacterial agents: a comprehensive review (2020-2024).Molecular diversity · 2026Review
- Gatifloxacin detection in the nanoscale: a review exploring current biosensing technologies and future opportunities.RSC advances · 2025Review
- Enhanced Detection of Bacterial Ocular Pathogens: A Comparative Study of Broad-Range Real-Time PCR and Conventional Culture Methods.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Targeted Bacterial Keratitis Treatment with Polyethylene Glycol-Dithiothreitol-Boric Acid Hydrogel and Gatifloxacin.Current drug delivery · 2024Article
- Gatifloxacin hydrochloride confers broad-spectrum antibacterial activity against phytopathogenic bacteria.Frontiers in microbiology · 2024Article
- Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?Pharmaceutics · 2023Review
- Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.Pharmaceutics · 2022Review
- Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.Pharmaceutics · 2021Review
- Piperazine based antimicrobial polymers: a review.RSC advances · 2021Review
- Evaluating the in vitro efficacy of gatifloxacin, levofloxacin and gentamicin against Acanthamoeba cysts.International ophthalmology · 2020Article
- Drug utilization study in ophthalmology outpatients at a tertiary care teaching hospital.ISRN pharmacology · 2013Article
- Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.Ophthalmology and eye diseases · 2012Article
- A Case-Control Study to Determine the Microbiological Spectrum and Antibiotic Sensitivity Patterns in Congenital Nasolacrimal Duct Obstruction.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial conjunctivitis is a common infectious disease of the eye, characterized by conjunctival hyperemia, eyelid edema, and purulent discharge. Although the prevalence and incidence are not well reported, bacterial conjunctivitis represents one of the most frequent causes of patient visits to both primary care physicians and ophthalmologists. Most cases of nongonococcal and nonchlamydial bacterial conjunctivitis are self-limiting and may resolve without intervention. There is a place for treatment, however, which allows for a shorter time to clinical and microbiological resolution which may decrease the mild morbidity, decrease health care costs of visits and potential complications, return patients back to school or the work force, and limit the potential spread of this communicable infection. Gatifloxacin ophthalmic solution is a broad spectrum 8-methoxyfluroroquinolone bactericidal antibiotic, with good activity against Staphylococcus aureus, Streptococcus species, and Gram-negative pathogens. It also has a relatively good resistance profile, making it a more than adequate choice in the treatment of bacterial conjunctivitis when therapy is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.